BioCardia (BCDA)
(Delayed Data from NSDQ)
$0.38 USD
+0.01 (2.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.39 +0.01 (3.56%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
BioCardia, Inc. (BCDA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.00 | $4.00 | $4.00 | 981.08% |
Price Target
Only one analyst offered a short-term price target of $4.00 for BioCardia, Inc. This represents an increase of 981.08% from the last closing price of $0.37.
Analyst Price Targets (1 )
Broker Rating
BioCardia, Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on three recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.33 | 2.33 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
7/28/2023 | Alliance Global Partners | Laura Suriel | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 2 |
Average Target Price | $4.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | NA |